Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Yonghua Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9973-8843; OpenAlex author ID A5100757194. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers

Papers 9

  1. Growth inhibition of pancreatic cancer by targeted delivery of gemcitabine via fucoidan-coated pH-sensitive liposomes. Co-author DOI 10.1016/j.ijbiomac.2024.134517↗
  2. Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/cad.0000000000001545↗
  3. Clusterin is upregulated by erastin, a ferroptosis inducer and exerts cytoprotective effects in pancreatic adenocarcinoma cells. Co-author DOI 10.1097/cad.0000000000001561↗
  4. Remnant Pancreas Volume Affects New-Onset Impaired Glucose Homeostasis Secondary to Pancreatic Cancer. Last author DOI 10.3390/biomedicines12081653↗
  5. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective… Co-author DOI 10.1002/cam4.5779↗
  6. Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm12030756↗
  7. The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/gs-21-859↗
  8. Comment on "Optimal Number of Examined Lymph Node May Dependent on Age in Patients With Pancreatic Adenocarcinoma". First author DOI 10.1097/sla.0000000000003811↗
  9. Disparities in survival by stage after surgery between pancreatic head and body/tail in patients with nonmetastatic pancreatic cancer. Co-author DOI 10.1371/journal.pone.0226726↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chunlu Tan · 8 shared papers, 2019–2024 · strength 1.60
  2. Xubao Liu · 6 shared papers, 2019–2024 · strength 1.10
  3. Zhenjiang Zheng · 5 shared papers, 2019–2024 · strength 0.96
  4. Qingquan Tan · 2 shared papers, 2023–2024 · strength 0.48
  5. Yichen Li · 2 shared papers, 2024 · strength 0.47
  6. Nengwen Ke · 2 shared papers, 2022–2023 · strength 0.37
  7. Xu-Bao Liu · 1 shared paper, 2024 · strength 0.26
  8. Xu-Bao Liu · 1 shared paper, 2024 · strength 0.26
  9. Jie Yang · 1 shared paper, 2024 · strength 0.26
  10. Xing Wang · 1 shared paper, 2024 · strength 0.26
  11. Xing Wang · 1 shared paper, 2023 · strength 0.22
  12. Guanhua Chen · 1 shared paper, 2023 · strength 0.22
  13. Xiaoding Shen · 1 shared paper, 2023 · strength 0.20
  14. Xing Wang · 1 shared paper, 2023 · strength 0.20
  15. Zhenjiang Zheng · 1 shared paper, 2021 · strength 0.19
  16. Chunlu Tan · 1 shared paper, 2021 · strength 0.19
  17. Epiphane K. Silli · 1 shared paper, 2024 · strength 0.18
  18. Ying Wang · 1 shared paper, 2024 · strength 0.18
  19. Junjie Xiong · 1 shared paper, 2022 · strength 0.16
  20. Yutong Yao · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.